<DOC>
	<DOCNO>NCT02243683</DOCNO>
	<brief_summary>The purpose study determine toxicity , tolerability safety single ascend dos AX-024.HCl healthy male subject .</brief_summary>
	<brief_title>Safety Study Immune System Modulator Autoimmune Diseases</brief_title>
	<detailed_description />
	<criteria>Subjects body mass index ( BMI ) 18 35 kg/m2 , inclusive . BMI = Body weight ( kg ) / [ Height ( ) ] 2 . In good health determine medical history , physical examination , clinical judgment investigator Subject history autoimmune disease cardiac disease Subjects must available complete study ( include followup visit ) . Subjects must satisfy medical examiner fitness participate study . Subjects must provide write informed consent participate study . A clinically significant history gastrointestinal disorder likely influence drug absorption . Receipt regular medication within 21 day first dose may impact safety objective study ( Investigator 's discretion ) . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . Subjects smoker , exsmokers smoke last 3 month ( determine negative urine cotinine screen visit ) . A clinically significant history hypersensitivity ( anaphylaxis , angioedema ) drug . A clinically significant history drug alcohol abuse . Participation New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month . ( N.B . washout period study define period time elapse last dose previous study first dose next study ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>